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We show that the mouse macrophage-restricted F4/80 protein is not required for the 
development and distribution of tissue macrophages but is involved in the generation of 
antigen-specific efferent regulatory T (T reg) cells that suppress antigen-specific immunity. 
In the in vivo anterior chamber (a.c.)–associated immune deviation (ACAID) model of 
peripheral tolerance, a.c. inoculation of antigen into F4/80
 
 
 
/
 
 
 
 mice was unable to induce 
efferent T reg cells and suppress delayed-type hypersensitivity (DTH) responses. Moreover, 
the use of anti-F4/80 mAb and F4/80
 
 
 
/
 
 
 
 APCs in an in vitro ACAID model showed that all 
APC cells in the culture must be able to express F4/80 protein if efferent T reg cells were to 
be generated. In a low-dose oral tolerance model, WT but not F4/80
 
 
 
/
 
 
 
 mice generated an 
efferent CD8
 
 
 
 T reg cell population that suppressed an antigen-specific DTH response. 
Peripheral tolerance was restored in F4/80
 
 
 
/
 
 
 
 mice by adoptive transfer of F4/80
 
 
 
 APCs in 
both peripheral tolerance models, indicating a central role for the F4/80 molecule in the 
generation of efferent CD8
 
 
 
 T reg cells.
 
As professional phagocytes and APCs, macro-
phages are important in the innate as well
as the adaptive immune system. In addition,
macrophages also play a central role in tissue
homeostasis, eliminating dying cells and nurs-
ing hemopoietic precursor cells (1). Many of
their important functions are performed by
cell-surface proteins, such as the complement
receptors, the mannose receptor, and scaven-
ger receptors (2, 3). The F4/80 glycoprotein,
identified more than 20 years ago as the anti-
gen for the F4/80 mAb, has been established as
one of the most specific cell-surface markers
for murine macrophages (4, 5). F4/80 is highly
and constitutively expressed on most resident
tissue macrophages, including the red pulp
macrophages in the spleen, microglia in the
brain, Kupffer’s cells in the liver, and Langerhans’
cells in the skin (6). Furthermore, the expression
of F4/80 is tightly regulated according to the
physiological status of cells. Thus, the precursor
of tissue macrophages, the blood monocyte, is
known to express less F4/80 than its mature
counterparts (7). F4/80 is expressed at lower
levels on activated macrophages isolated from
bacille Calmette-Guérin–infected animals than
on unstimulated resting macrophages (8). Sim-
ilarly, F4/80 expression is down-regulated on
macrophages in response to IFN-
 
 
 
 (9). F4/80
expression on Langerhans’ cells decreases after
they take up antigens and become migrating
DCs; in lymph nodes and spleens, F4/80 is
detected only on macrophages in T cell–inde-
pendent areas (7). These studies have pointed
to a function for F4/80 in selected tissue mac-
rophage populations.
Analysis of the F4/80 protein sequence re-
vealed an intriguing hybrid structure consisting
of motifs of two different protein superfamilies
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(10, 11). The epidermal growth factor (EGF)-like domains
are located at the extracellular NH
 
2
 
 terminus, whereas a
seven-span transmembrane (TM7) domain similar to the class
B G-protein–coupled receptors is located at the COOH ter-
minus. Hence, F4/80 is a prototypic member of the EGF-
TM7 receptor family that includes EGF module–containing
mucin-like hormone receptor (EMR)1, 2, 3, 4, EGF-TM7-
latrophilin–related protein (ETL) and CD97 (6, 12). The
EGF-like module, which often occurs as multiple tandem re-
peats, has been identified in a wide variety of extracellular
proteins involved in adhesion, receptor–ligand interactions,
extracellular matrix structure, and the determination of cell
fate (13). The TM7/G-protein–coupled receptor domain,
on the other hand, has been shown to mediate the signal
transduction of an extensive array of exogenous stimuli in-
cluding hormones, cytokines, peptides, amino acid deriva-
tives, ions, neurotransmitters, and sensory stimuli such as
photons, taste, and odorants (14, 15). A dual adhesion and
signaling function has thus been suggested for the EGF-TM7
molecules in which the extracellular region is involved in
protein–protein interaction with other cell-surface proteins
and/or extracellular matrix proteins, triggering intracellular
signaling through the TM7 domain. Consistent with this hy-
pothesis, specific cellular ligands for the EGF-TM7 receptors
have been reported. CD55 (decay accelerating factor, DAF)
was identified as the cognate cellular receptor for CD97 (16).
More recently, we have identified cell-surface chondroitin
sulfate as a specific ligand for the largest isoform of EMR2
and CD97 (17). Similarly, the presence of putative cell-sur-
face ligands for EMR3 and EMR4 has also been demon-
strated (18, 19). It is therefore reasonable to suggest that F4/
80 may have a similar cell adhesion function, which in turn
might influence the development, distribution and functions
of tissue macrophages in vivo.
Peripheral tolerance in the adult serves to prevent im-
mune recognition by self-reactive lymphocytes as well as to
prevent inappropriate immune reactivity. F4/80
 
 
 
 APCs have
previously been shown to carry a tolerance-inducing signal
in a model of peripheral immune tolerance known as ante-
rior chamber–associated immune deviation (ACAID)(20–
22). ACAID-induced peripheral tolerance is both local and
peripheral in its effects and helps protect the delicate struc-
ture of the visual axis from the devastating effects of immu-
nogenic inflammation. Foreign antigens that enter the eye
are captured by indigenous APCs of the iris and ciliary body
that then travel via the blood to the spleen where they facili-
tate antigen-specific tolerance. Both CD4
 
 
 
 and CD8
 
 
 
 T
regulatory (T reg) cells are generated to suppress the afferent
and efferent arms of the immune response, respectively. Dur-
ing ACAID induction, F4/80
 
 
 
 APCs appear first in the
bloodstream and then in the splenic marginal zones where
the production of macrophage inflammatory protein 2 by
these APCs is critical to the recruitment of CD1d-restricted
NK T cells for the induction of tolerance (23, 24). It has
been shown that ACAID can be induced in naive mice with
the adoptive transfer of as few as 20 F4/80
 
 
 
 APCs generated
in vitro by treatment with TGF-
 
 
 
2 and antigen (22). As in
the ACAID model, a low-dose oral tolerance model in mice
generates CD8
 
 
 
 T reg cells capable of suppressing Th1 effec-
tor functions (25). In addition, as in the eyes, some indige-
nous macrophages in the Peyer’s patches also express the F4/
80 antigen (26). Because of the similarities in these two toler-
ance models, we postulated a direct role for the F4/80 mole-
cule in the induction of peripheral tolerance. F4/80-deficient
mice were generated via gene targeting to delineate the role
of F4/80 in the development and distribution of tissue mac-
rophages and to investigate whether F4/80 itself is involved
in the induction of peripheral tolerance.
 
RESULTS
The normal development of macrophages in 
 
F4/80
 
 
 
/
 
 
 
 mice
 
An 
 
F4/80
 
-targeting construct was prepared by replacing an
 
 
 
1.0-kb HindIII–XbaI fragment containing the coding se-
quence of the first exon and the 5
 
 
 
-end of the first intron
with a promoterless 
 
 
 
-galactosidase/pGK-Neo cassette. The
homologous regions in both arms of the targeting construct
are a 1.8-kb fragment 5
 
 
 
 to the first exon and a 2.8-kb frag-
ment containing the exon 2 and the 3
 
 
 
-end of intron 1 (Fig.
1 A). F4/80
 
   
 
 animals were bred to produce mutant mice,
which were identified by genotyping of tail DNA using
Southern blot hybridization (Fig. 1 B). The presence of a
14-kb HindIII fragment detected by probe A and the ab-
sence of probe B–hybridized DNA fragments in F4/80
 
 
 
/
 
 
 
DNA samples indicated that homologous recombination had
indeed occurred at the 
 
F4/80
 
 locus. This result was further
verified by PCR genotyping analysis in which only the 300-
bp fragments specific to the 
 
F4/80
 
-targeted alleles, but not
the WT allele–specific 600-bp fragments, were amplified in
F4/80
 
 
 
/
 
 
 
 DNA samples (Fig. 1 B). Northern blot hybridiza-
tion and RT-PCR analyses showed that no F4/80 transcript
was identified in the mutant animals (Fig. 1, C and D). Like-
wise, no F4/80 protein expression was identified in the F4/
80
 
 
 
/
 
 
 
 mice using both polyclonal and monoclonal anti-F4/
80 antibodies (Abs) in immunohistochemistry and flow cy-
tometry (Fig. 1 E and Table I). The complete absence of the
F4/80 transcript and protein in F4/80
 
 
 
/
 
 
 
 mice indicates a
F4/80 null mutation. The F4/80
 
 
 
/
 
 
 
 mice appear healthy,
have normal bodyweight, and are fertile. Histological exam-
ination of various organs and tissues including bone marrow,
liver, lung, kidney, heart, spleen, thymus, and lymph nodes
from F4/80
 
 
 
/
 
 
 
 animals failed to show any gross abnormali-
ties (unpublished data). Flow cytometric analysis also indi-
cated that the development of B and T lymphoid cells in the
mutant mice is not affected (Table I and Figs. S1–S3, avail-
able at http://www.jem.org/cgi/content/full/jem.20042307/
DC1). To investigate whether the characteristics of tissue
macrophage populations were affected by the inactivation of
the 
 
F4/80
 
 gene, the expression profiles of various macro-
phage-restricted cell-surface proteins, including the comple-
ment receptor 3, class-A scavenger receptor, macrosialin, 
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and sialoadhesin, were examined. No difference in expres-
sion patterns of these molecules was observed between F4/
80
 
 
 
/
 
 
 
 mice and the WT controls (Fig. 2 and unpublished
data). In addition, subpopulations of myeloid cells in blood
and spleen, as detected by a panel of cell-surface markers, in-
cluding CD11b, 
 
 
 
-glucan receptor (Dectin-1), Gr-1, 7/4,
and mannose receptor, were all comparable in WT and F4/
80
 
 
 
/
 
 
 
 mice (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20042307/DC1). Other phenotypic char-
acterization between the WT and F4/80
 
 
 
/
 
 
 
 mice was found
to be similar and is summarized in Table I. For functional
characterization, the binding and phagocytosis of zymosan
and opsonized sheep red blood cells by thioglycollate-elic-
ited macrophages were found to be similar in both WT and
F4/80
 
 
 
/
 
 
 
 cells (Fig. S2, available at http://www.jem.org/
cgi/content/full/jem.20042307/DC1). The production of
nitric oxide and inflammatory/antiinflammatory cytokines
such as TNF-
 
 
 
, IL-10, and IL-12 in Bio-gel–elicited perito-
neal macrophages treated with LPS and/or IFN-
 
 
 
 was mea-
sured. Again, no difference was observed in cells from the
WT and F4/80
 
 
 
/
 
 
 
 mice (Fig. S3, available at http://www.
jem.org/cgi/content/full/jem.20042307/DC1). Thus, we
conclude that F4/80 is not necessary for the development
and distribution of mouse tissue macrophage populations,
and the inactivation of 
 
F4/80
 
 does not affect the general cel-
lular functions of macrophages analyzed by conventional
functional assays.
 
The role of F4/80 in the generation of CD8
 
 
 
 T reg cells in an 
in vivo ACAID tolerance model
 
ACAID is a model for peripheral tolerance that is initiated
by inoculation of antigen into the anterior chamber (a.c.)
(for review see reference 27). Early reports showed that
ACAID-inducing signals were carried from the eye to the
spleen via APCs in the blood that expressed F4/80 protein
(20, 21, 28). At that time, F4/80 Ab given in vivo was able
to prevent the suppression of delayed-type hypersensitivity
(DTH; ACAID) in experimental mice (20). However, the
mechanism of the Ab treatment or the role of F4/80 protein
in the model has not been studied further until now.
It is well established that a.c. inoculation of antigens leads
to the development of splenic CD8
 
 
 
 efferent T reg cells that
Figure 1. Gene targeting of the mouse F4/80 gene. (A) Partial re-
striction maps of the mouse F4/80 gene, the targeting construct, and the 
resulting targeted allele. The  -galactosidase and pGK-Neo gene cassettes 
are shown as black and white boxes, respectively. White boxes with numbers 
indicate exons. The 5 -UTR is represented by a stippled box. DNA probes A 
and B used for Southern blot analysis are shown. The expected HindIII 
fragments of the WT (10.2 kb) and the targeted alleles (14.0 kb) detected 
by probes A and B are also shown. Arrows with numbers indicate the 
positions and orientations of the primers used for the PCR genotyping 
reaction. (B) Southern blot and PCR genotyping. Tail DNA was digested 
with HindIII and hybridized with probe A (top) and probe B (middle). The 
same genomic DNA was analyzed using primers 1, 2, and 3. (C) Northern 
blot hybridization and (D) RT-PCR analysis of total RNA from thymus of 
F4/80 / ,  / , and  /  animals using (C) the full-length F4/80 cDNA 
probe and (D) primers specific for the F4/80 (top) and Hprt (bottom) 
cDNAs. (E) mAb F4/80 staining in the spleens and livers (Kupffer’s cells, 
arrow) of the F4/80 /  and  /  animals. Magnification at 200 (spleen), 
400 (liver). 
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actively suppress an antigen-specific DTH response (29, 30).
To test if the F4/80 protein had a functional role in the gen-
eration of ACAID-induced CD8
 
 
 
 T reg cells, we inoculated
OVA into the a.c. of WT and F4/80
 
 
 
/
 
 
 
 mice, collected
their splenic T cells, and examined their ability to suppress
OVA-specific effector T cell function in a local adoptive
transfer (LAT) assay. The LAT assay tests for efferent T reg
cell function. It is established that the cells that affect this
function are CD8
 
 
 
 (30). In brief, enriched splenic T cells
(regulatory cells) were collected from a.c.-inoculated mice
and mixed equally with OVA-pulsed peritoneal exudate
cells (PECs) (stimulators) and OVA-primed T cells (effec-
tors). The cell mixture (1.5 
 
 
 
 10
 
5
 
 cells total in 10 
 
 
 
l HBSS)
was then injected intradermally to the ear pinnae of unma-
nipulated B6 mice. 24 h later, the ear swelling response was
measured as an indicator of DTH. Splenic T cells from naive
B6-WT mice did not suppress the adoptively transferred
DTH response, whereas splenic T cells from WT mice inoc-
ulated with OVA (a.c.) did suppress the response (Fig. 3). In
contrast, splenic T cells from OVA-inoculated (a.c.) F4/80
 
 
 
/
 
 
Figure 2. Immunohistochemical analysis of the F4/80 /  macrophage. 
mAb 3D6 (anti-sialoadhesin) staining in the (A, B) livers and (C, D) and spleens 
of the (A, C) F4/80 /  and (B, D)  /  animals. 3D6  Kupffer’s cells and 
macrophages (brown) were found in the livers and the red pulp and marginal 
zone areas of spleens of both (A, C) F4/80 /  and (B, D)  /  mice. The stron-
gest 3D6 staining is on macrophages in the inner region of the marginal zone 
(marginal metallophils), forming a tight ring (arrow) around the white pulp 
(C, D). Magnification at 400 (A, B), 200 (C, D). (E, F) mAb 5C6 staining in the 
spleens and (G, H) mAb FA-11 staining in the livers of the (E, G) F4/80 /  and 
(F, H)  /  animals. mAb FA-11 is specific for macrosialin (mouse CD68), 
whereas mAb 5C6 specifically recognizes type 3 complement receptor on 
myeloid cells. Magnification at 200 (E, F), 400 (G, H).
 
Table I.
 
Summary of the phenotypic analysis of the F4/80 mutant mice
 
Genotype
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
Progeny no. 168/700 (24.0%) 358/700 (51.1%) 174/700 (24.9%)
RPC
 
a
 
8.35 
 
  0.54 8.07   1.07 8.08   1.48
TPCb 3.10   0.26 ND 2.96   0.15
Mac1  cells (RPC, TPC)c 37.5%, 78.4% ND 37.7%, 76.5%
Mac1 F4/80  cells (RPC, TPC)c 35.2%, 58.1% ND 0.1%, 0.23%
CD4 CD8  cells (spleen, thymus)d 0.81%, 73.1% ND 1.20%, 74.2%
CD4 CD8  cells (spleen, thymus) 16.3%, 17.6% ND 15.9%, 16.8%
CD4 CD8  cells (spleen, thymus) 4.50%, 4.10% ND 4.90%, 3.80%
B220 Thy1  cellse 67.9% ND 68.3%
B220 Thy1  cells 15.1% ND 14.3%
aTotal RPCs isolated by peritoneal lavage. Cells were counted by hemocytometer. Numbers given are cell number   10 6; n   8.
bTotal TPCs isolated by peritoneal lavage 4 days after thioglycollate injection. Numbers given are cell number   10 7; n   10.
cFlow cytometric analysis of RPC and TPC using Mac1 and F4/80 mAbs. Numbers given are percentage of single- and double-positive cells from one representative experiment.
dFlow cytometric analysis of splenic and thymic cells using CD4 and CD8 mAbs.
eFlow cytometric analysis of spenic cells using B220 and Thy1 mAbs.
RPC, resident peritoneal cells; TPC, thioglycollate-elicited peritoneal cells.JEM VOL. 201, May 16, 2005 1619
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mice failed to suppress the DTH response. Therefore, we
concluded that peripheral tolerance that developed subse-
quent to a.c. inoculation of antigen failed in F4/80 /  mice
because of a lack of efferent T reg cell development.
The role of F4/80 in the generation of T reg cells for 
peripheral tolerance in vitro
It is known that inoculation of antigen via the a.c. results in
the appearance of tolerance-inducing F4/80  cells in the pe-
ripheral blood within 3 d (20, 31). To quantify the changes in
the blood-borne F4/80  cell population, PBMCs from
OVA-inoculated (either i.v. or a.c.) and naive mice were col-
lected and stained with FITC- F4/80 mAb. The F4/80  cell
population constituted 6% of the total PBMC population
(5.97   104 F4/80  cells/106 PBMCs) in naive mice but in-
creased to nearly 14% of the total PBMC population (1.38  
105 F4/80  cells/106 PBMCs) in a.c.-inoculated mice (Fig. 4
A). Unlike the a.c. route, i.v. inoculation of OVA was not as-
sociated with an increase in the number of circulating F4/
80  cells (Fig. 4 A). Similarly, immunostaining of spleen sec-
tions from a.c.- but not i.v.- or s.c.-inoculated animals re-
vealed a marked increase in the number of F4/80  cells
forming cell clusters with NKT and conventional T cells in
the splenic marginal zones (unpublished data).
We postulated that if APCs were to induce ACAID and
generate efferent T reg cells, they must express F4/80 pro-
tein. To investigate whether the F4/80 molecule itself is in-
volved in peripheral tolerance, a combination of PECs from
F4/80 /  and WT mice and anti-F4/80 mAb or a control
rat IgG were used in an in vitro ACAID model of T reg cell
generation (32). The in vitro ACAID model allowed us to
manipulate the cells involved. Instead of collecting limited
numbers of APCs from the peripheral blood of a.c.-inocu-
lated animals, we generated an established surrogate ACAID
APC to induce ACAID in vitro. In brief, thioglycollate-
elicited PECs from either F4/80 /  or WT mice were cul-
Figure 3. The role of F4/80 in the generation of regulatory T cells 
in vivo after a.c. inoculation of antigen. Enriched splenic T cells were 
collected from WT and F4/80 /  mice that had received a.c. OVA 7 d earlier 
and were mixed with WT, OVA-pulsed PECs, and OVA-primed T cells. The 
cell inoculum was given intradermally to the pinnae of naive B6 mice. Ear 
thickness was determined before and at 24 and 48 h after injection. Data 
are represented as mean change in ear thickness at 24 h after injection   
SEM. The composition of the cell inoculum is indicated under each bar in 
the graph. *, P   0.01; n   5/group.
Figure 4. The role of F4/80 in the generation of regulatory T cells 
in vitro. (A) Assessment of F4/80  cells in the circulation after a.c. or i.v. 
inoculation of antigen. The bar graph represents the number of F4/80  
cells per million blood mononuclear cells in naive mice and 3 d after a.c. or 
i.v. inoculation of OVA. The number of F4/80  cells was determined from 
four pooled, splenectomized mice for the a.c. and i.v. groups and five mice 
from a control group. The data shown are representative of two experi-
ments in which similar results were obtained. (B) Generation of T reg cells 
with F4/80 /  APC in the presence or absence of anti F4/80 mAb. The bar 
graph shows the magnitude of ear swelling (ordinate) as a measure of DTH 
responses generated in naive B6 mice. Mice were given an intradermal ear 
injection of a cell mixture containing OVA-primed spleen cells and T reg 
cells. T reg cells were generated by coculturing naive spleen cells for 5 d 
with WT or F4/80 /  PECs that had been treated overnight with OVA with 
or without TGF 2. Before the addition of the naive spleen cells, cells were 
cultured in presence or absence of anti-F4/80 mAb. Ear thickness was 
determined before ear pinnae injection and at 24 and 48 h after injection. 
*, P   0.01; n   5/group.F4/80 IS REQUIRED FOR PERIPHERAL TOLERANCE | Lin et al. 1620
tured overnight in the presence or absence of OVA with or
without TGF- 2. The cultured PECs were washed to re-
move excess antigen and TGF- . Because the PECs from
the KO mice lack only the F4/80 protein, we expected
them to respond as WT mice to the TGF- 2 treatment. In-
deed TGF- 2–treated WT and F4/80 /  PECs produce
TGF-  (J. Stein-Streilein, unpublished data) and have the
capacity to “educate” other APCs in the culture to acquire
ACAID-inducing qualities. Therefore to control for the
ability of TGF- 2–treated F4/80-deficient APCs influenc-
ing F4/80  splenic cells and to determine if there were a re-
quirement for F4/80 expression on splenic APCs as well as
the ACAID-inducing APCs, naive syngeneic spleen cells
were added to the PECs and cultured for 5 d in the pres-
ence or absence of either anti-F4/80 mAb or control rat
IgG. At the end of the PEC–spleen cell coculture, nonad-
herent cells were collected, enriched for T cells, and tested
for efferent T reg cell function in the LAT DTH assay. T
cells from cocultures with OVA-pulsed PECs from WT
mice that had been pretreated with TGF- 2 (ACAID
PECs) were found to suppress the DTH response signifi-
cantly (Fig. 4 B). TGF- 2 is a major constituent of the
aqueous humor (33, 34) and is one of the key molecules
that endow resident eye-derived macrophages with tolero-
genic potential (31). If the OVA-pulsed TGF- 2–treated
PECs were harvested from F4/80 /  mice and cultured
with naive spleen cells in the presence of control rat IgG,
there was partial suppression of DTH. However, when both
treated F4/80 /  PEC and naive spleen cells were cultured
in the presence of anti-F4/80 mAb, there was no evidence
of a functional efferent regulatory cell being generated (Fig.
4 B). Thus F4/80 protein must be expressed on the OVA-
pulsed TGF- –treated APCs and on APCs within the WT
spleens to induce the T reg cell in vitro.
The role of F4/80 in the generation of CD8  T reg cells in a 
low-dose oral tolerance model
To determine whether the role for the F4/80 molecule in
the generation of CD8  T reg cells is unique to ACAID, we
tested the role of F4/80 in a low-dose oral tolerance model
that is also known to generate CD8  T reg cells (25). Al-
Figure 5. The role of F4/80 in the generation of regulatory T cells 
in vivo after low-dose oral gavage of antigen. (A) Low-dose oral toler-
ance experiments in WT and F4/80 /  mice: the ear swelling DTH response 
to OVA of F4/80 /  mice immunized with OVA in CFA s.c. and ear challenged 
with OVA intradermally in the ear pinnae (positive DTH) versus those fed 
OVA (gavage). The treatment of the mice is indicated below the abscissa 
under each bar. Naive F4/80 /  mice that received only OVA by ear challenge 
served as the negative DTH control. The number (n) and treatment of the 
mice are indicated along the abscissa under each bar graph. The change in 
ear thickness is listed on the ordinate. (B) Low-dose antigen gavage gener-
ated an efferent T reg cell in WT but not in F4/80 / mice. 7 d after OVA-
gavage, enriched T cells from spleens were mixed with primed T cells 
(effector) and OVA-pulsed APCs (stimulator) before being injected into the 
ear pinnae of naive mice. Phenotype of the cells in the mixture injected is 
indicated under the abscissa. The change in ear swelling is indicated on 
the ordinate. *, P   0.05. (C) LAT assay for efferent CD8  T reg cells in WT 
mice that received antigen by gavage. 7 d after OVA-gavage, T cells were 
enriched from spleens and were either depleted of CD4  T cells (GK1.5 and 
complement), depleted of CD8  T cells (2.43 and complement), or kept un-
manipulated. The enriched T cells were mixed with primed T cells (effector) 
and OVA-pulsed APCs (stimulator) before being injected into the ear pinnae 
of naive mice. The phenotype of the cells in the mixture injected is indi-
cated under the abscissa. The change in ear swelling is indicated on the 
ordinate. *, P   0.05. Depletion of cells was confirmed using flow cytometry 
(not depicted).JEM VOL. 201, May 16, 2005 1621
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though both high-dose and low-dose gavage of antigen can
induce oral tolerance, only the low-dose procedure induces
CD8  T reg cells. Briefly, WT and F4/80 /  mice were
given 5 mg of OVA in saline by gavage. 1 wk later, experi-
mental mice and a set of naive mice (positive control) were
sensitized with OVA in CFA (s.c.). After another 7 d, the ear
pinnae were inoculated intradermally with antigen-pulsed
syngeneic PEC. The DTH response was suppressed in WT
mice that received OVA by gavage but was apparent in both
the positive control and the F4/80 /  mice that had re-
ceived antigen by gavage (Fig. 5 A). To confirm that the tol-
erance response observed here is caused by the generation of
efferent T reg cells, another low-dose oral tolerance experi-
ment was performed. 7 d after mice received OVA by ga-
vage, T cells were enriched from spleens and mixed with
primed T cells (effectors) and OVA-pulsed APCs (stimula-
tors) before being injected into the ear pinnae of naive mice.
As expected, enriched T reg cells from OVA-gavaged WT
mice were able to suppress the DTH response, whereas the
cells from OVA-gavaged F4/80 /  mice did not (Fig. 5 B).
To demonstrate the phenotype of the T reg cell that was
suppressing the DTH response, we repeated the LAT assays
using enriched splenic T cells from OVA-gavaged mice that
were unmanipulated or were depleted of either CD4  or
CD8  T cells before mixing with the effector and stimulator
cells. Cells were depleted of the CD4  or CD8  T cell sub-
sets by incubation with GK1.5 or 2.43 mAb and comple-
ment, respectively. We observed that the enriched T cells
were able to suppress the adoptively transferred response
when the sample was unmanipulated or was depleted of
CD4  T cells but not when the CD8  T cells were re-
moved (Fig. 5 C). These observations confirm that, like
ACAID, low-dose oral tolerance generates efferent CD8  T
reg cells that efficiently suppress the effector phase of a DTH
response. Thus the F4/80 protein is required for the process
that leads to the generation of CD8  T reg cells in at least
Figure 6. Reconstitution of F4/80 /  mice with F4/80  APC restores 
peripheral tolerance. (A) To demonstrate antigen specificity of efferent 
suppression in two models of tolerance where animals received OVA either 
by intracameral inoculation or gavage before challenge in the ear with 
OVA or human serum albumin (HSA) (unrelated antigen). The change in 
ear swelling is on the ordinate, and the antigen regimen is displayed below 
bars under the abscissa. (B) In the ACAID tolerance model, F4/80 /  mice 
were reconstituted with 106 F4/80  bone marrow–derived APCs (BMAPCs) 
1 d before inducing ACAID with OVA a.c. (C) In the low-dose oral tolerance 
model, F4/80 /  mice were reconstituted with 106 F4/80  BMAPCs . The 
experiment was repeated twice with similar results. (D) F4/80 /  mice 
were reconstituted with 106 F4/80  adherent spleen cells. The next day, 
mice were given OVA gavage, and 7 d later they were immunized with OVA 
s.c. After another week, they were challenged intradermally in the ear. DTH 
responses were measured as an increase in ear thickness. The treatment of 
the mice is indicated below the abscissa under each bar. The change in ear 
thickness is indicated on the ordinate. Significant (P   0.05) differences 
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two models of peripheral tolerance: the ACAID and low-
dose oral tolerance.
Reconstitution of the F4/80  cells in F4/80 /  mice and 
restoration of peripheral tolerance
Although it is well established that the efferent T reg cell is
antigen specific (27), we confirmed here that in both ACAID
and low-dose oral tolerance (Fig. 6 A) the suppression of
DTH in the ear occurred only when the specific antigen in-
oculated into the eye or introduced into the gut was used for
challenge (Fig. 6 A). To establish the role of F4/80 in both
peripheral tolerance models unambiguously, we next restored
the F4/80  cell populations in the F4/80 /  mice by transfer-
ring WT APCs into mutant mice before the beginning of ei-
ther tolerance protocol. Separate groups of mice that were in
the ACAID (Fig. 6 B) or low-dose oral tolerance (Fig. 6, C
and D) protocol received 106 F4/80  bone marrow–derived
APCs (BMAPCs) or F4/80  adherent splenic cells per mouse.
All cells expressed F4/80 protein as determined by flow cy-
tometry (unpublished data). F4/80 /  mice receiving no WT
APCs were used as controls. We noticed that there was an in-
significant suppression of DTH in the F4/80 /  mice that
were gavaged but not reconstituted (Fig. 6, C and D). There
may also be mechanisms that are F4/80-independent that
contribute to suppression of DTH in oral tolerance. How-
ever, this possibility does not detract from our interpretation
of Fig. 6, that both reconstitution protocols restore the ability
of the previously deficient mice to respond to a.c. inoculation
or gavage of OVA with the development of T reg cells.
DISCUSSION
To study the biological functions of the F4/80 protein, we
have generated a mouse strain in which the F4/80 gene is
mutated and the synthesis of the F4/80 protein is disrupted
(Fig. 1). No apparent abnormal phenotypes were identified in
the F4/80 /  mice, indicating that F4/80 is dispensable for
the development of mouse tissue macrophages. Schaller et al.
recently also reported the generation of another strain of F4/
80-deficient mice by knocking in Cre recombinase under the
control of the F4/80 gene promoter (35). Consistent with our
finding, the normal homeostatic development of macrophages
was observed in F4/80Cre/Cre mice (35). Similarly, no obvious
phenotypic changes were found in the F4/80Cre/Cre mice,
even after infection with live Listeria monocytogenes.
Nevertheless, other reports have implicated F4/80 in
macrophage functions in pathological and inflammatory situ-
ations. A functional requirement for F4/80 in the produc-
tion of TNF , IL-12, and IFN-  after exposure of the
mouse spleen cells to either heat-killed or viable Listeria
monocytogenes has been demonstrated (36). In this model, F4/
80 has been shown to be involved in direct cell–cell contact
between macrophages and NK cells that results in cell activa-
tion and optimal cytokine production. Also noteworthy is
the identification of an eye-derived F4/80  cell as the cell
that carries the ACAID-inducing signal to the spleen (20,
21, 28, 31). Wilbanks et al. went on to show that in vivo
treatment of a.c.-inoculated mice with F4/80 Ab prevented
the suppression of DTH (ACAID) in the mice (20). As a re-
sult, F4/80 became a marker of the “eye-derived” APCs that
were central to the induction of ACAID. Here, and in pre-
vious reports from our laboratory, we show that, after a.c.
inoculation of the antigen, F4/80  cells accumulate in the
marginal zone of the spleen, forming clusters with NK T
cells and conventional T cells (24). This observation is in
keeping with other observations that F4/80  cells, although
present abundantly in the red pulp (37), are normally absent
in T cell areas and in the marginal zones (7). If the F4/80
protein becomes a marker for tolerogenic APCs, its function
may be relevant to our hypothesis that tolerance induction
occurs in non–T cell areas of the secondary lymphoid or-
gans. Future studies regarding the function of F4/80 protein
during tolerance induction will help us to explore this idea.
The interaction between F4/80 CD1d  tolerogenic
APCs and NK T cells was essential for the development of
CD8  T reg cells capable of suppressing DTH toward eye-
derived antigens (23). These results prompted us to ask
whether the F4/80 molecule itself plays a direct role in the
induction of peripheral tolerance. We showed here that not
only do F4/80  APCs increase in the blood and then in the
spleen after an inoculation of antigen into the eye, but that
the F4/80 molecule is important for the generation of effer-
ent T reg cells (Figs. 3 and 4). It is well established in the
ACAID literature that the efferent T reg cell is CD8  and
antigen specific (30, 38). This is further supported by our re-
port that the ACAID efferent regulatory T cell is easily gen-
erated in class II–deficient mice, a strain that has no conven-
tional CD4  T cells (39).
Additionally, we showed that the requirement of F4/80
is not unique to CD8  T reg cell generation in the ACAID
model; F4/80 is also needed for CD8  T reg cell induction
in low-dose oral tolerance (Fig. 5). This is the first report of
a role for the F4/80 molecule in the induction of CD8  T
reg cells and in peripheral tolerance. Although oral tolerance
shares some properties with ACAID, there are also differ-
ences between the two models. First, the environment of the
gut is not generally considered to be immune privileged, be-
cause it is not a site that normally accepts foreign grafts (27).
However, the gut does have a complicated cascade of events
that prevents certain types of immune responses to ingested
protein antigens. One of the similarities is that both the eye
and the gut contain large amounts of TGF-  (34, 40–42).
Moreover, as in ACAID we observed that low-dose oral tol-
erance is dependent on the presence of the invariant NK T
cell because J 18-deficient mice that lack the invariant NKT
cell are unable to acquire tolerance after low-dose antigen
gavage (unpublished data) (43). Class II–deficient mice are
still able to generate T cells capable of suppressing the DTH
effector function of T cells in both models. Also, we show
here that the efferent regulatory function is antigen specific
in both models of tolerance.JEM VOL. 201, May 16, 2005 1623
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Although the gut/intestine is not considered to be an
immune privileged site (27), an essential feature of the intes-
tinal immune system is its ability to discriminate between
harmful and harmless foreign proteins (44). Under normal
conditions, the individual is tolerant to soluble food antigens
but is capable of mounting effective immune responses when
confronted with invasive organisms. The mechanism of oral
tolerance is unclear and may result from deletion, anergy, or
active regulation of immune effector cells (45, 46). It is
thought that the diverse local APCs present in the intestine
play a major role in determining the T cell response to anti-
gen (47). It is believed that mucosal DCs may in their native
state preferentially behave as tolerogenic APCs. Many of the
APCs in Peyer’s patches constitutively secrete immunosup-
pressive cytokines such as IL-10 (48, 49). It is interesting that
the APCs in the Peyer’s patches also express F4/80 protein
(26). In keeping with the idea that the F4/80 molecule may
identify tolerogenic APCs, Suter et al. recently reported that
the majority of DCs in the brain/central nervous system, an-
other immune privileged site where tolerance is promoted,
also expressed F4/80 (50). Our studies here show that the
F4/80 protein on APCs is needed for the generation of the
CD8  T reg cells in oral tolerance and provide evidence that
suppression of DTH responses may be transferred with
CD8  T cells after antigen gavage (Fig. 5 C). Currently, we
are characterizing the surface phenotype of the F4/80 
tolerogenic APCs in the ACAID model. We find that the
F4/80  APCs lack coreceptors for T cell activation and do
not up-regulate CCR-7, the chemokine receptor that guides
APCs to the T cell areas of the secondary lymphoid organs
(J. Zhang-Hoover, J. Stein-Streilein, unpublished data).
Given the lack of a known ligand for F4/80, it remains
difficult to define a molecular mechanism mediating the dif-
ferentiation of CD8  T reg cells. It is plausible that F4/80
serves to stabilize adhesive interactions between APCs and
other cell types including NK cells or NK T cells. This idea is
consistent with the observation that Langerhans’ cells down-
regulate F4/80 expression after taking up antigen to become
veiled cells that migrate via the lymph to regional nodes. Also
supporting an adhesive function for the F4/80 molecule is
the observation that circulating blood monocytes express
lower cell surface levels of F4/80 than do tissue macrophages
(7). Alternatively, it is possible that the F4/80 molecule, once
engaged by its ligand, participates in intracellular signaling
events that lead to APC cytokine production that facilitates T
cell differentiation. The development of a functional soluble
form of the F4/80 ligand may allow us to determine whether
signaling through the F4/80 molecule triggers activation, dif-
ferentiation, or cytokine production by APCs.
In this report we show for the first time that the F4/80
molecule is required for the differentiation of antigen-spe-
cific CD8  T reg cells, a process that requires direct cellular
interaction of CD1d  APCs with NK T cells. There are
many correlations with NK T cell activation in self-tolerance
and their deficiencies in autoimmune diseases such as diabe-
tes, multiple sclerosis, and lupus (51, 52). Identifying the cel-
lular and molecular mechanisms used by the F4/80 molecule
to facilitate the differentiation of T reg cells will contribute
to our understanding of the processes involved in immuno-
logical tolerance and/or its breakdown.
MATERIALS AND METHODS
Antibodies. For the in vitro assays, anti-F4/80 mAb was purified from
F4/80 hybridoma supernatants and used at a concentration of 10  g/ml. Ab
3D6, 2F8, 5C6, and FA-11 were specific to sialoadhesin, macrophage class-A
scavenger receptor, the type 3 complement receptor, and macrosialin, re-
spectively. mAbs used for flow cytometric and tissue staining analysis were
phycoerythrin (PE)-conjugated anti–mouse CD4 Ab (0.5 mg/ml; Caltag
Laboratories), FITC-conjugated anti–mouse CD8 Ab (0.5 mg/ml; Caltag Lab-
oratories), FITC-conjugated anti–mouse Thy-1.2 Ab (1 mg/ml; Caltag Labo-
ratories), PE- and Rhodamine-conjugated anti–mouse B220 Ab, Rhoda-
mine-conjugated anti–mouse CD3 Ab (BD Biosciences), FITC-conjugated
anti–mouse Mac-1 Ab (BD Biosciences), PE-conjugated anti–mouse F4/80
Ab (Serotec), and PE- or FITC-conjugated rat IgG2b(K) Ab (BD Bio-
sciences) as isotype control. Anti–mouse Fc II/IIIR Ab was used to block
nonspecific binding of Abs through Fc.
Construction of the F4/80 targeting vector. To make the F4/80 gene-
targeting construct, a 1.8-kb EcoRI-HindIII fragment containing the 5 -UTR
of the F4/80 gene was subcloned into the NotI and HindIII sites of the pSA
 -galactosidase–Neo vector (53). A 2.8-kb XbaI–EcoRI fragment contain-
ing exon 2 of the F4/80 gene was then inserted into the previous construct
through the XbaI and KpnI sites. The completed construct, pF4/80  -galac-
tosidase, resulting in the deletion of the exon 1 coding sequence of the F4/80
gene, is shown in Fig. 1 A.
Mice. The targeting construct, pF4/80– -galactosidase, was linearized
with KpnI and electroporated into CJ7 mouse embryonic stem (ES) cells as
described previously (54). Genomic DNA isolated from the resulting ES
cell clones was analyzed by Southern blot hybridization using HindIII di-
gestion and a 32P-labeled 0.2 kb EcoRI–BamHI fragment (probe A in Fig. 1
A). Microinjection of targeted ES cells to C57BL/6J blastocysts and the
generation of heterozygous and homozygous mice were performed as de-
scribed previously (54). Gene targeting was confirmed by Southern blot
analysis of tail DNA and the PCR genotyping reaction using a primer spe-
cific for the  -galactosidase gene (primer 1: 5 -TCCGCCATGTCAC-
AGATCAT-3 ) and two F4/80 gene-specific primers (primer 2: 5 -
GGAAGGAAATGGAGAGAAAG-3 , and primer 3: 5 -GAAGATCT-
ACCCTGGTGAAT-3 ) (Fig. 1). The F4/80 /  mice were backcrossed to
C57BL/6 (B6-WT) background for more than 10 generations (B6-F4/80 / ).
All animals were treated humanely and in accordance with the guidelines
set forth by the Animal Care and Use Committee of Sir William Dunn
School of Pathology, Schepens Eye Research Institute, and the National In-
stitute of Health.
Northern blot hybridization and RT-PCR analysis. Total RNA iso-
lated from thymus, spleen, and liver of 5-wk-old F4/80  / ,  / , and  / 
mice was analyzed by Northern blot hybridization using a full-length F4/80
cDNA probe and by RT-PCR using gene-specific primers (5 -AGGACTG-
GAAGCCCATAGCCAA-3 , and 5 -GCATCTAGCAATGGACAGCTG-
3 ) as described previously (11). Primers for the hypoxanthine-guanine phos-
phoribosyl transferase (Hprt) gene were included as an internal control.
Immunohistochemical and flow cytometric analysis. Immunohis-
tochemical staining of tissue sections of F4/80  / ,  / , and  /  mice
was performed as described (55). Flow cytometric analyses were done on an
EPICS XL flow cytometer (Beckman Coulter). The percent of F4/80  cells
was determined after gating on the entire viable PBMC population. TheF4/80 IS REQUIRED FOR PERIPHERAL TOLERANCE | Lin et al. 1624
absolute number of F4/80  cells per 106 PBMCs was calculated according
to the percentage of F4/80  cells found in the total number of cells ob-
tained per milliliter of blood.
Cell enrichment. PBMCs used in the flow cytometric analyses were iso-
lated from heparinized venous blood obtained at 3 and 7 d after a.c. inocu-
lation of antigen. PBMCs were enriched by density-gradient centrifugation
using Lympholyte-M (Cedarlane Laboratories, Ltd.). Splenic T cells used
for the LAT assay (described below) were enriched using IMMULAN T
cell enrichment columns (Biotecx Laboratories, Inc.). Resident peritoneal
macrophages (RPM ) and thioglycollate-elicited peritoneal macrophages
(TPM ) were obtained from 8–10-wk-old mice. TPM  were harvested
from animals injected i.p. with 1.0 ml of 3.0% (wt/vol) sterile Brewer’s
thioglycollate medium (Difco) 4 d earlier.
Antigen inoculations. For i.v. and s.c. administration of antigen, each
mouse received 50  g OVA in 100  l HBSS via the tail vein or subcutane-
ously, respectively. For a.c. inoculation of antigens, mice were anesthetized
with ketamine/xylazine as described previously (23, 24). All OVA solutions
were passed through DetoxiGelAffinityPakpolymyxin B columns (Pierce
Chemical Co.) to remove contaminating endotoxin/LPS.
LAT assay. LAT was used to test for the presence or absence of regulatory
CD8  T cells as described previously (23, 24). In brief, OVA-primed effec-
tor T cells were generated by immunizing C57BL/6 mice with OVA in
CFA (Sigma-Aldrich). 7 d later the spleens were collected and enriched for
T cells. T reg cells were enriched from the spleens of either B6-WT or B6-
F4/80 /  mice that had received OVA or HBSS (a.c.) 7 d earlier. Stimulator
cells were obtained by culturing thioglycollate-elicited PECs with 5 ng/ml
OVA overnight. Stimulator, effector, and regulatory cells (5   105 each)
were resuspended in 10  l HBSS and injected intradermally into the pinnae
of naive mice. The change in ear thickness was measured at 24 and 48 h after
challenge using an engineer’s micrometer (Mitutoyo/MTI Corporation).
Induction of oral tolerance and DTH assay. Tolerance induction, sen-
sitization, and challenge were performed using OVA that had been depleted
of contaminating endotoxin by passage over a Detoxi Gel column (Pierce
Chemical Co.). Oral tolerance was induced by feeding mice OVA (5 mg in
200  l PBS) by gavage after mice had been deprived of food for 4–6 h. 7 d
after induction of oral tolerance, mice were sensitized s.c. with 150  l of an
emulsion of endotoxin-free OVA (2.0 mg/ml in PBS) and CFA. 1 wk after
sensitization, mice were challenged intradermally with OVA-pulsed PECs
(2.0   105 cells in 10  l PBS) into the pinnae. The change in the ear thick-
ness was measured 24 h later as an indication of the DTH response.
Preparation of BMAPCs and adherent spleen cells for reconstitu-
tion experiments. BMAPCs were generated by culturing bone marrow
cells in L929-conditioned growth medium (10% L929-conditioned me-
dium, 10% horse serum, 10% controlled-process serum replacement type 3)
for 6 d (56). The cells were collected; cell viability was  90%. Collected
APCs were washed and resuspended in HBSS before i.v. inoculation of 106
cells per mouse. Spleens were removed from killed mice, dissociated into
single cell suspensions, and layered on Petri dishes at a concentration of 2  
106 cells/ml in HBSS in 10% FBS. After a 90-min incubation at 37 C, the
nonadherent cells were washed away, and the adherent cells were harvested.
The expression of F4/80 on BMAPCs and adherent spleen cells was con-
firmed by immunostaining and flow cytometry (unpublished data).
Statistical analyses. All statistical analyses were performed by analysis of
variance with Neuman-Keuls post hoc analyses. Significance was deter-
mined at P   0.05.
Online supplemental material. Fig. S1 depicts flow cytometric charac-
terization of the myeloid cell populations in peripheral blood (A) and spleen
(B) of WT and F4/80 KO mice. Fig. S2 shows a quantitative phagocytic as-
say of the WT and F4/80 KO thioglycollate-elicited microphage. Fig. S3
depicts NO and cytokine production of Bio-gel–elicited macrophages from
the WT and F4/80 KO mice (Fig. 3). Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20042307/DC1.
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